Are Biotech Investors Still Being Led By Science Fundamentals?

From the Aduhelm approval to exuberant stock markets, life sciences investor and In Vivo Rising Leader John Cassidy shares insights into industry trends, highlighting areas where decisions may have moved away from scientific fundamentals.